Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

p> personnel and the costs the Company's clinical trials and research

initiatives, were $3.5 million in the fourth quarter of 2007, down from

$5.5 million in the previous quarter and $6.3 million in the fourth

quarter of 2006. R&D expenses declined for the full year of 2007 to

$22.0 million, compared to $26.0 million in the prior year. Reduced R&D

expenses resulted mainly from lower spending on the Company's MOXATAG

clinical trial which concluded in 2006.

Selling, general and administrative (SG&A) expenses totaled $5.6

million in the fourth quarter of 2007, down from $6.5 million in the

third quarter of 2007, and $8.3 million in the fourth quarter of 2006.

Fourth quarter SG&A costs declined due to lower third-party costs

associated with the reduced size of Company's contract sales force. For

the full year of 2007, SG&A expenses increased to $26.0 million, from

$21.3 million, as the Company incurred a full year of Keflex 750

selling and marketing expenses in 2007, versus incurring such costs

only during a portion of 2006.

-- Other expenses for the fourth quarter of 2007 included a $2.1 million

noncash expense for the contractual value of warrants issued to

Deerfield Management pursuant to the Keflex transaction in the quarter.

There were no such expenses in prior periods.

-- Net loss for the fourth quarter of 2007 was $9.1 million. This compares

to a net loss of $10.1 million in the third quarter of 2007, and $13.8

million in the fourth quarter of 2006. Net loss for the full year of

2007 was $42.2 million, compared to a net loss of $42.0 million for the

full year of 2006. The net loss for the three months and full year

ended December 31, 2007, was reduced by $0.2 million attributable to

the loss from noncontrolling interest in two compani
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 According ... Product (1D & 2D Gel Electrophoresis, Agarose & Polyacrylamide ... Reagents, Informatics), by Application & by End User - ... Market is expected to reach around $1.98 Billion by ... period 2015 to 2020. Browse 226 ...
(Date:5/22/2015)... 2015 Baylor Research Institute (BRI) at ... Research Institute (TGen) in Phoenix, AZ ... early detection and treatments for patients with a broad range ... lead to new clinical trials and access to technology to ... from bench to bedside across Baylor Scott & ...
(Date:5/21/2015)... Specialty Pharmacy Times has completed ... to BPA Worldwide as a business publication member. ... data for Specialty Pharmacy Times based on business/distribution, ... a member of BPA Worldwide, Specialty Pharmacy Times ... with the most reliable, unequaled data,” said Chris ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 uBiome, ... announced a partnership with PicnicHealth, a healthcare company ... Participants diagnosed with Inflammatory Bowel Disease (IBD) will ... a complementary uBiome research kit. Both companies were ... , For more information on this ...
Breaking Biology Technology:Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Specialty Pharmacy Times Joins BPA Worldwide 2uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3
... Health Care (IHC) have announced a plan to ... adoption of electronic health records among U.S. health-care providers. ... Information and Management Systems Society (HIMSS) meeting in Dallas ... knowledge that IHC has gathered over the years and ...
... or process, having the next big thing is not ... marketplace, a mid-sized firm occupying several hard-won niches, or ... your success, says Tom Miller, an intellectual property lawyer ... a recent presentation to eInnovate, a Milwaukee-based technology forum, ...
... Small Tree Communications , a niche hardware ... a $445,000 funding round from Chippewa Valley Angel Investors ... to grow our business faster by getting our products to ... "It'll allow us to get office space and equipment, and ...
Cached Biology Technology:GE and Intermountain want to streamline nationwide patient data 2Protect your intellectual property before it's too late 2Protect your intellectual property before it's too late 3Chippewa Valley angels invest in network hardware company 2Chippewa Valley angels invest in network hardware company 3
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... ( www.ucr.edu ) The lab of a ... was named on Tuesday, April 3 after Innovation Economy ... research focused on using mobile devices, such as cell ... The technology being developed by Nosang Myung, professor and ...
... 30 millionth species occurrence record last week, making it ... animals and fungi. The Atlas, a collaboration between ... and Southern Cross Universities and the Commonwealth Government, reached ... Birdlife Australia were incorporated. Some of these records come ...
... A new gene that causes early-onset of Alzheimer,s disease has ... the Insert unit 1079 "Genetics of cancer and neuropsychiatric diseases" ... of 5 of 14 patients suffering from the disease, mutations ... production of a peptide involved in Alzheimer,s disease. The results ...
Cached Biology News:Using cell phones to detect harmful airborne substances 217th century Dutch explorers help the Atlas reach a major milestone -- 30 million records 2A new gene thought to be the cause in early-onset forms of Alzheimer's disease 2
Mouse monoclonal [SPM302] to BCAR1, prediluted ( Abpromise for all tested applications). entrezGeneID: 9564 SwissProtID: P56945...
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
Biology Products: